close El 76 % de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor. Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento. El 76 % de inversores minoristas pierde dinero al operar CFDs con este proveedor. Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
BuscarBuscar
Change languageEspañol
Dashboard

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

Inicio・Lista de Acciones・Lyell Immunopharma Inc
Search

Lyell Immunopharma Inc

Abierto

8.69 -3.98

Vender

Precios actualizados 27 jun 2025, 19:30 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

8.57

Máximo

9.25

Métricas clave

By Trading Economics

Ingresos

140M

-52M

Ventas

-4K

7K

BPA

-3.6

Margen de beneficios

-745,642.857

Empleados

300

EBITDA

3.7M

-54M

Recomendaciones

By TipRanks

Recomendaciones

Vender

Estimación a 12 Meses

+18.41% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

133M

Apertura anterior

12.67

Cierre anterior

8.69

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

0.4217 / 0.4691 Soporte y Resistencia

Lyell Immunopharma Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 jun 2025, 23:49 UTC

Ganancias

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

DJ

Leer

26 jun 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

DJ

Leer

26 jun 2025, 21:30 UTC

Ganancias

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

DJ

Leer

26 jun 2025, 21:07 UTC

Ganancias

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

DJ

Leer

26 jun 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

DJ

Leer

26 jun 2025, 23:39 UTC

Charlas de Mercado

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

DJ

Leer

26 jun 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

DJ

Leer

26 jun 2025, 23:33 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

DJ

Leer

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers Will No Longer Receive Earnings From BWP Management

DJ

Leer

26 jun 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

DJ

Leer

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

DJ

Leer

26 jun 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

DJ

Leer

26 jun 2025, 23:30 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

DJ

Leer

26 jun 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

DJ

Leer

26 jun 2025, 23:19 UTC

Adquisiciones, fusiones, absorciones

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

DJ

Leer

26 jun 2025, 22:06 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

DJ

Leer

26 jun 2025, 21:15 UTC

Ganancias

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

DJ

Leer

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

DJ

Leer

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

DJ

Leer

26 jun 2025, 21:07 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

DJ

Leer

26 jun 2025, 21:07 UTC

Ganancias

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

DJ

Leer

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

DJ

Leer

26 jun 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

DJ

Leer

26 jun 2025, 21:06 UTC

Charlas de Mercado

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

DJ

Leer

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

DJ

Leer

26 jun 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

DJ

Leer

26 jun 2025, 20:52 UTC

Ganancias

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

DJ

Leer

26 jun 2025, 20:51 UTC

Ganancias

Correct: Nike 4Q Net $211M, Not $200M >NKE

DJ

Leer

26 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

DJ

Leer

26 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

DJ

Leer

Comparación entre iguales

Cambio de precio

Lyell Immunopharma Inc previsión

Precio Objetivo

By TipRanks

18.41% repunte

Estimación a 12 Meses

Media 11 USD  18.41%

Máximo 12 USD

Mínimo 10 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lyell Immunopharma Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

3 ratings

0

Comprar

2

Mantener

1

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Lyell Immunopharma Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.4217 / 0.4691Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Medio plazo

Weak Bearish Evidence

There is one bearish event.

Largo Plazo

No Evidence

There are no events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Otras acciones del sector

LLY

Eli Lilly and Co.

775.15

↓-2.1%

JNJ

Johnson and Johnson

152.39

↑ +0.45%

ABBV

AbbVie Inc

184.42

↓-0.99%

NVO

Novo Nordisk A-S

68.11

↑ +0.95%

UNH

UnitedHealth Group Inc

306.72

↑ +1.67%